Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or VSports app下载. mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure V体育官网. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. .

. 2023 Jan 4:13:1054508.
doi: 10.3389/fphys.2022.1054508. eCollection 2022.

Effect of the 3q26-coding oncogene SEC62 as a potential prognostic marker in patients with ovarian neoplasia

Julia C Radosa  1 , Mariz Kasoha  1 , Anne-Christine Schilz  1 , Zoltan F Takacs  1 , Askin Kaya  1 , Marc P Radosa  2 , Barbara Linxweiler  1 , Maximilian Linxweiler  3 , Rainer M Bohle  4 , Mathias Wagner  4 , Gudrun Wagenpfeil  5 , Erich-Franz Solomayer  1 , Julia S M Zimmermann  1
Affiliations

Effect of the 3q26-coding oncogene SEC62 as a potential prognostic marker in patients with ovarian neoplasia

"VSports手机版" Julia C Radosa et al. Front Physiol. .

Abstract

With approximately 220,000 newly diagnosed cases per year, ovarian cancer is among the most frequently occurring cancers among women and the second leading cause of death from gynecological malignancies worldwide. About 70% of these cancers are diagnosed in advanced stages (FIGO IIB-IV), with a 5-year survival rate of 20-30%. Due to the poor prognosis of this disease, research has focused on its pathogenesis and the identification of prognostic factors. One possible approach for the identification of biological markers is the identification of tumor entity-specific genetic "driver mutations". One such mutation is 3q26 amplification in the tumor driver SEC62, which has been identified as relevant to the pathogenesis of ovarian cancer. This study was conducted to investigate the role of SEC62 in ovarian malignancies. Patients with ovarian neoplasias (borderline tumors of the ovary and ovarian cancer) who were treated between January 2007 and April 2019 at the Department of Gynecology and Obstetrics, Saarland University Hospital, were included in this retrospective study VSports手机版. SEC62 expression in tumor tissue samples taken during clinical treatment was assessed immunohistochemically, with the calculation of immunoreactivity scores according to Remmele and Stegner, Pathologe, 1987, 8, 138-140. Correlations of SEC62 expression with the TNM stage, histological subtype, tumor entity, and oncological outcomes (progression-free and overall survival) were examined. The sample comprised 167 patients (123 with ovarian cancer and 44 with borderline tumors of the ovary) with a median age of 60 (range, 15-87) years. At the time of diagnosis, 77 (46%) cases were FIGO stage III. All tissue slides showed SEC62 overexpression in tumor cells and no SEC62 expression in other cells. Median immunoreactivity scores were 8 (range, 2-12) for ovarian cancer and 9 (range, 4-12) for borderline tumors of the ovary. Patients with borderline tumors of the ovary as well as patients with ovarian cancer and an immunoreactive score (IRS) ≤ 9 showed an improved overall survival compared to those presenting with an IRS score >9 (p = 0. 03). SEC62 seems to be a prognostic biomarker for the overall survival of patients with ovarian malignancies. .

Keywords: 3q26 amplification; Sec62; borderline tumors of the ovary; ovarian cancer; prognostic; therapy; tumor driver mutation. V体育安卓版.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Sec62 immunohistochemistry. (A) Negative SEC62 expression in normal ovarian tissue, as well as low (B), moderate (C), and high immunostaining intensity (D) in serous ovarian cancer. SEC62 expression is indicated by a red signal, counterstaining with hematoxylin (blue).
FIGURE 2
FIGURE 2
Sec62 immunohistochemistry stainings: Tissue samples of serous ovarian cancer and serous borderline tumors of the ovary. (A) Serous ovarian cancer with Sec62 immunoreactive score (IRS) 3, (B) serous ovarian cancer with Sec62 immunoreactive score (IRS) 4, (C) serous ovarian cancer with Sec62 immunoreactive score (IRS) 8, (D,E) serous ovarian cancer with Sec62 immunoreactive score (IRS) 9, (F) serous ovarian cancer with Sec62 immunoreactive score (IRS) 12, (G) serous borderline tumors of the ovary with Sec62 immunoreactive score (IRS) 4, (H) serous borderline tumors of the ovary with Sec62 immunoreactive score (IRS) 6, (I) serous borderline tumors of the ovary with Sec62 immunoreactive score (IRS) 8, (J) serous borderline tumors of the ovary with Sec62 immunoreactive score (IRS) 9.
FIGURE 3
FIGURE 3
Survival rates for ovarian cancer patients and patients with borderline tumors of the ovary of the Department of Gynecology and Obstetrics, Saarland University Hospital, Homburg, Germany, between January 2007 and April 2019. (A) Progression-free and overall survival in the whole cohort. (B) Progression-free and overall survival in invasive ovarian cancer. (C) Progression-free and overall survival in borderline tumors of the ovary. Sec62 immunoreactive score (IRS) > 9, Sec62 IRS ≤9. Two-sided p values are indicated, values <0.05 were considered to be significant.
FIGURE 4
FIGURE 4
Type and frequency of reported SEC62 gene alterations and related survival rates. (A) Type and frequency of SEC62 gene alterations recorded in the TCGA atlas from the National Cancer Institute GDC Data Portal. The analysis was performed in 86,046 cases overall from 67 different primary tumor sites on 13 July 2022. CNA = copy number alteration (B) Overall survival across all cancer entities recorded in the TCGA atlas depending on SEC62 alteration. The analysis was performed on 13 July 2022. Two-sided p values are indicated, values <0.05 were considered to be significant.
See this image and copyright information in PMC

VSports - References

    1. Benedet J. L., Bender H., Jones H., 3rd., Ngan H. Y., Pecorelli S. (2000). FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int. J. Gynaecol. Obstet. 70, 209–262. 10.1016/S0020-7292(00)90001-8 - DOI - PubMed
    1. Bochen F., Adisurya H., Wemmert S., Lerner C., Greiner M., Zimmermann R., et al. (2017). Effect of 3q oncogenes SEC62 and SOX2 on lymphatic metastasis and clinical outcome of head and neck squamous cell carcinomas. Oncotarget 8, 4922–4934. 10.18632/oncotarget.13986 - DOI (VSports在线直播) - PMC - PubMed
    1. Bristow R. E., Tomacruz S. R., Armstrong D. K., Trimble E. L., Montz F. J. (2002). Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J. Clin. Oncol. 20, 1248–1259. 10.1200/JCO.2002.20.5.1248 - DOI - PubMed
    1. Buys S. S., Partridge E., Black A., Johnson C. C., Lamerato L., Isaacs C., et al. PLCO Project Team (2011). Effect of screening on ovarian cancer mortality: The prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial. JAMA 305, 2295–2303. 10.1001/jama.2011.766 - DOI - PubMed
    1. Cancer Genome Atlas Research Network (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061–1068. 10.1038/nature07385 - DOI - PMC - PubMed